폐암 치료제 : 세계 시장

The global market for lung cancer therapeutics is expected to grow from $32.5 billion in 2025 and is projected to reach $49.5 billion by the end of 2030, at a compound annual growth rate (CAGR) of 8.8% during the forecast period of 2025 to 2030.

The North American market for lung cancer therapeutics is expected to grow from $17.4 billion in 2025 and is projected to reach $26.7 billion by the end of 2030, at a CAGR of 8.9% during the forecast period of 2025 to 2030.

The European market for lung cancer therapeutics is expected to grow from $7.9 billion in 2025 and is projected to reach $11.9 billion by the end of 2030, at a CAGR of 8.3% during the forecast period of 2025 to 2030.

Report Scope

This report will provide detailed information on lung cancer therapeutics. This report analyzes the market trends for lung cancer therapeutics, providing data for 2024, estimates for 2025, projections of compound annual growth rates (CAGRs) through 2030 (forecast period: 2025-2030) and regional markets for lung cancer therapeutics. This report will highlight the current and future market potential of lung cancer therapeutics, providing a detailed analysis of the competitive environment. The report will cover regulatory scenarios, drivers, restraints and opportunities, as well as market projections for 2030 and the market share for key market players.

In this report, the market is segmented by cancer type into non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). By therapeutic type, the market is segmented into targeted therapy, chemotherapy and immunotherapy.

The market has been segmented into five regions: North America, Europe, Asia-Pacific, the Middle East and Africa (MEA), and South America. This report will also provide detailed analyses of major countries, including the U.S., Canada, Mexico, Germany, the U.K., France, Italy, Spain, Japan, China, South Korea, Australia and India. For market estimates, data will be provided for 2024, given the base year, along with data for 2025 and a forecast value for 2030.

The report aims to:

• Analyze types of lung cancer therapeutics.
• Analyze global market size and segments.
• Understand market constraints and drivers.
• Provide detailed market forecasts for 2030.
• Assess market shares, competitiveness and industry structure.
• Identify potential long-term impacts on the lung cancer therapeutics market.

Report Includes

• 86 data tables and 55 additional tables
• An overview of the global market for lung cancer therapeutics
• In-depth analysis of global market trends, featuring historical revenue data for 2022-2025, as well as forecasts for 2030. This analysis includes projections of compound annual growth rates (CAGRs) through 2030
• Evaluation of the current market size and revenue growth prospects specific to the lung cancer therapeutics, accompanied by a market share analysis by type, therapeutics, and region
• Analysis of current and future demand in the lung cancer therapeutics market, along with a detailed analysis of the competitive environment, market regulations and reimbursement practices
• Analysis of drivers, challenges, and opportunities affecting market growth
• Coverage of evolving technologies, the current and future market potential, R&D activities, clinical trials, growth strategies, new product pipeline, regulatory framework and reimbursement scenarios, and ESG trends of the market
• Market share analysis of the key market participants in the industry, along with their research priorities, product portfolios, global rankings and company competitive landscape
• Profiles of major companies within the industry, including AstraZeneca, Merck & Co. Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Bristol-Myers Squibb Co., and Pfizer Inc.

Table of Contents

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Summary
• Market Dynamics and Growth Factors
• Emerging Technologies
• Segmental Analysis
• Regional Analysis
• Conclusion

Chapter 2 Market Overview

• Overview
• Macroeconomic Factors Analysis
• Impact of U.S. Tariffs on the Pharmaceutical Industry
• Healthcare Expenditure
• Geopolitical Risks, Trade Wars and Supply Chain Disruptions
• Impact of Global Economic Growth (GDP) on the Pharma Sector
• Porter's Five Forces Analysis
• Bargaining Power of Buyers
• Bargaining Power of Suppliers
• Threat of Substitutes
• Competitiveness in the Industry

Chapter 3 Market Dynamics

• Market Dynamics
• Market Drivers
• Rising Lung Cancer Cases
• Increasing Innovation in Lung Cancer Therapeutics
• Increasing R&D Spending by Market Players
• Rise in Government Funding and Pharmaceutical R&D Spending
• Market Restraints
• Rising Generic Competition and Patent Expiration
• Shortage of Oncology Professionals
• Available Low-Priced Chemotherapeutics Limiting Growth of Advanced Therapies
• Market Opportunities
• Increasing Demand for Novel Therapies
• Emerging Markets
• Increasing Lung Cancer Incidence Among Non-Smokers

Chapter 4 Regulatory Landscape

• Overview
• U.S.
• Europe
• Asia-Pacific

Chapter 5 Emerging Technologies and Pipeline Analysis

• Overview
• Artificial Intelligence
• Immunotherapies and Cell Therapy
• Emergent Biomarkers
• Clinical Trial Analysis
• Clinical Trials Analysis by Type of Study
• Clinical Trials Analysis by Status
• Clinical Trials Analysis by Phase
• Key Takeaways
• Patent Analysis
• Key Takeaways

Chapter 6 Market Segment Analysis

• Segmentation Breakdown
• Global Market for Lung Cancer Therapeutics, by Cancer Type
• Key Takeaways
• Non-Small Cell Lung Cancer
• Small Cell Lung Cancer
• Global Market for Lung Cancer Therapeutics, by Therapeutic
• Key Takeaways
• Targeted Therapy
• Chemotherapy
• Immunotherapy
• Geographic Breakdown
• Global Market for Lung Cancer Therapeutics, by Region
• Key Takeaways
• North America
• Europe
• Asia-Pacific
• Middle East and Africa
• South America

Chapter 7 Competitive Intelligence

• Key Takeaways
• Competitive Landscape
• Company Share Analysis
• Strategic Analysis

Chapter 8 Sustainability in the Global Market for Lung Cancer Therapeutics: An ESG Perspective

• Introduction to ESG
• Sustainability in the Lung Cancer Therapeutics Market
• ESG Perspective
• Environmental Impact
• Social Impact
• Governance Impact
• ESG Risk Ratings
• Conclusion

Chapter 9 Appendix

• Methodology
• Abbreviations
• Sources
• Company Profiles
• ABBVIE INC.
• AMGEN INC.
• ASTRAZENECA
• BOEHRINGER INGELHEIM INTERNATIONAL GMBH
• BRISTOL-MYERS SQUIBB CO.
• F. HOFFMANN-LA ROCHE LTD.
• JAZZ PHARMACEUTICALS INC.
• JOHNSON & JOHNSON
• LILLY USA LLC.
• MERCK & CO. INC.
• NOVARTIS AG
• PFIZER INC.
• REGENERON PHARMACEUTICALS INC.
• TAKEDA PHARMACEUTICAL CO. LTD.
• TEVA PHARMACEUTICAL INDUSTRIES LTD.
• Emerging Players/Market Disruptors